ArticleBioprocess and biosystems engineering2026
Biosynthesis of cyanophycin by high-cell-density cultivation of recombinant Escherichia coli for corrosion-resistant biomaterial applications.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyanophycin granule polypeptide (CGP), also known as multi-L-arginyl-poly(aspartic acid), is a biodegradable biopolymer composed primarily of aspartic acid and arginine. Due to its versatile functional properties, CGP has attracted increasing interest for potential applications in food, medicine, cosmetics, agriculture, and corrosion inhibition. The objective of this study was to biosynthesize a biologically derived corrosion-inhibiting biomaterial using recombinant Escherichia coli BL21(DE3) expressing cyanophycin synthetase (CphA), followed by cost-effective induction strategy. Specifically, this work aimed to establish a high-cell-density cultivation process capable of achieving improved CGP production while reducing dependence on costly inducers such as IPTG. Initial shake-flask experiments demonstrated that lactose induction resulted in higher CGP production and biomass formation compared to IPTG induction. In addition, supplementation with phosphate, ribose, trace elements, yeast extract, and tryptone further improved CGP accumulation. Based on these findings, a high-cell-density fed-batch fermentation strategy using lactose as both inducer and carbon source was developed, maximum gravimetrically recovered crude soluble and insoluble CGP-containing fractions of 35.4 and 17.8 g/L. Product characterization was further supported by FTIR, XRD, MALDI-MS. Furthermore, the recovered CGP-related material was evaluated in preliminary corrosion inhibition experiments under acidic conditions and showed significant reduction in corrosion rates compared with untreated control samples, indicating its potential for future corrosion-protection applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.